Introduction
Materials and methods
Results
Histological analysis
Patient no | Primary diagnosis | Revised diagnosis | Methods and basis for reclassification | |
---|---|---|---|---|
1 | MEC | MASC HG | FISH | Translocation ETV6-NTRK3 |
2 | ACa NOS | MASC HG | FISH | Translocation ETV6-NTRK3 |
3 | ACa NOS | MASC LG | FISH | Translocation ETV6-NTRK3 |
4 | AcCC | MASC LG | FISH | Translocation ETV6-NTRK3 |
5 | AcCC | MASC LG | FISH | Translocation ETV6-NTRK3 |
6 | Papillary CAC | MASC LG | FISH | Translocation ETV6-NTRK3 |
7 | UCa | NCa | IHC | Chromogranin+, CD56+, synaptophysin+, TTF1−, S100−, CK20−, CK7− |
8 | SCC G2 | SDC | IHC | AR−, HER2+, CK7+, p63−, S100− |
9 | CxPA | SDC | IHC | AR+ (20 %), HER2+, CK7+ |
10 | MEC HG | SDC | IHC | AR+, HER2+, CK7+, p63−, S100−, EMA+ |
11 | MEC HG | SDC | IHC | AR−, HER2+, CK7+, p63−, S100−, EMA+ |
12 | ACa NOS | AcCC | IHC | CK8+, CK7−, PAS+, DOG1+ |
13 | AdCC | AcCC | IHC | DOG1+, PAS+ |
14 | MEC | EMCa LG | IHC | P63+, CK7+, CK14+, calponin focally+ |
15 | BCAca | EMCa LG | IHC | P63+, CK7+, CK14+, calponin+ |
16 | AcCC | EMCa LG | IHC | P63+, CK7+, CK14+, calponin+ |
17 | CxPA (SDC) | CXPA in situ | H&E | |
18 | CxPA (ACa NOS) | CXPA in situ | H&E | |
19 | CxPA | PA with SCM | H&E | Lack of atypia |
20 | MEC | PA with SCM | H&E/FISH | Lack of translocation CTRC1-MAML2/CTRC3-MAML2 |
21 | Clear cell Ca | Myoepithelioma (clear cell variant) | IHC | S100+, SMA+, calponin+, GFAP+ |
22 | MEC | Metaplastic WT | H&E/FISH | Lack of translocation CTRC1-MAML2/CTRC3-MAML2 |
23 | PLGA |
Necrotizing sialometaplasia
| H&E | |
24 | MEC | SCC metastases (skin) | H&E/clinical data/follow-up | PAS−, mucicarmine− |
25 | Clear cell Ca | RCC metastases | IHC/clinical data/follow-up | CD10+, RCC+ |
26 | AcCC | RCC metastases | IHC/clinical data/follow-up | CD10+, RCC+ |
27 | AcCC | RCC metastases | IHC/clinical data/follow-up | CD10+, RCC+ |
28 | AcCC | BC metastases | IHC/clinical data/follow-up | Mammaglobin + |
Clinical analysis
No | Age | Sex | Primary histology | Grade | TNM | Resection | Revised histology | Status/years |
---|---|---|---|---|---|---|---|---|
1 | 60 | M | MEC | IG | pT4aN1 | R1 + RT | MASC HG | DOD/1 |
2 | 73 | M | ACa NOS | HG | pT3N0 | R1 + RT | MASC HG | L/NR/2,3,4 |
3 | 63 | M | ACa NOS | LG | pT3N0 | R1 + RT | MASC LG | NED/9 |
4 | 51 | K | AcCC | LG | pT2N0 | R0 | MASC LG | NED/7 |
5 | 75 | K | AcCC | LG | pT3N0 | R1 | MASC LG | NED/5 |
6 | 42 | K | Papillary CAC | LG | pT2N0 | R0 | MASC LG | NED/9 |
7 | 46 | K | UCa | IG | pT2N0 | R0 | NCa IG | NED/20 |
8 | 71 | K | SCC | HG | pT3N2b | Rx + RT | SDC HG | DOD/3 |
9 | 57 | M | CxPA | HG | pT4aN1 | R1 + RT | SDC HG | DOD/1 |
10 | 67 | M | MEC | HG | pT4aN2b | R1 + RT | SDC HG | DOD/2 |
11 | 47 | K | MEC | HG | pT4aN2b | Rx + RT | SDC HG | NED/20 |
12 | 48 | K | ACa NOS | IG | pT2N0 | R0 | AcCC LG | NED/19 |
13 | 62 | M | AdCC | HG | pT2N0 | R0 | AcCC HG | LNR/3 |
14 | 75 | M | MEC | IG | pT2N0 | R0 | EMCa LG | NED/6 |
15 | 52 | K | BCAca | LG | pT2N0 | R1 + RT | EMCa LG | LR/2,4,9 |
16 | 67 | M | AcCC | LG | pT2N0 | R0 | EMCa LG | NED/15 |
17 | 42 | M | CxPA (SDC) | HG | pT3N0 | Rx | CxPA in situ | NED/15 |
18 | 51 | M | CxPA (ACa NOS) | HG | pT2N0 | R0 | CxPA in situ | NED/9 |
19 | 40 | K | CxPA (ACa NOS) | pT2N0 | R0 | PA with SCM | NED/17 | |
20 | 71 | K | MEC | IG | pT2N0 | R0 | PA with SCM | DOC/10 |
21 | 42 | K | Clear cell Ca | LG | pT2N0 | Rx | Myoepithelioma | NED/9 |
22 | 56 | M | MEC | LG | pT2N0 | R0 | Metaplastic WT | NED/9 |
23 | 35 | K | PLGA | LG | pT2N0 | R1 | Necrotizing sialometaplasia | NED/5 |
24 | 70 | M | MEC | pT2N1 | R0; RT | SCC metastases (skin) | NED/6 | |
25 | 68 | M | Clear cell Ca | LG | pT2N0 | R0 | RCC metastases | DOD/2 |
26 | 65 | K | AcCC | LG | pT1N0 | R0 | RCC metastases | DOD/2 |
27 | 76 | K | AcCC | LG | pT2N0 | Rx | RCC metastases | AWD/4 |
28 | 75 | K | AcCC | LG | pT1N0 | R0 | BC metastases | NED/10 |